CELL

ELFBAR launches CR600: a stylish and flavourful vape experience

Retrieved on: 
Thursday, February 8, 2024

Crafted for convenience, the device fits in the palm of hands, making it a stylish accessory for on-the-go vaping.

Key Points: 
  • Crafted for convenience, the device fits in the palm of hands, making it a stylish accessory for on-the-go vaping.
  • Equipped with QUAQ MESH coil technology, ELFBAR Crystal ensures a smooth, consistent and intensely flavourful vaping experience with every puff.
  • ELFBAR Crystal features a metallised casing with an LED light indicator, complementing its stylish design and providing functionality by indicating the device's power status for a user-friendly experience.
  • Offering premium quality at an affordable price, ELFBAR Crystal represents excellent value for money in the vape market.

GMG's Graphene Aluminium-Ion Battery: 1000 mAh Capacity Reached and Next Steps Toward Commercialisation

Retrieved on: 
Tuesday, February 6, 2024

Notably, this update includes information about GMG's G+AI Battery regarding:

Key Points: 
  • Notably, this update includes information about GMG's G+AI Battery regarding:
    The Company is pleased to announce it has now produced multiple battery pouch cells with over 1000 mAh (1 Ah) capacity, as seen in Figure 1.
  • In a recent build to confirm repeatability, the Company's development team has built and confirmed multiple cells, all testing greater than 1Ah (1000mAh).
  • To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/196983_dda901c7a4d06811_001fu...
    Please see charging and discharging curve typical of the GMG's Graphene Aluminium-Ion Battery 1000 mAh cell in Figure 2 showing a nominal voltage of 1.7 volts.
  • Oct 2022 - Significant battery performance, cell and graphene production improvements
    Feb 2023 - Australian Government Approval (AICIS) for production and sale of batteries.

Isuzu, Honda Begin Demonstration Testing Today of Fuel Cell-Powered Heavy-duty Truck on Public Roads in Japan

Retrieved on: 
Monday, December 25, 2023

TOKYO, Dec 25, 2023 - (JCN Newswire) - Isuzu Motors Limited and Honda Motor Co., Ltd. today began demonstration testing on public roads in Japan of the GIGA FUEL CELL, a fuel cell (FC)-powered heavy-duty truck currently being co-developed by the two companies.

Key Points: 
  • TOKYO, Dec 25, 2023 - (JCN Newswire) - Isuzu Motors Limited and Honda Motor Co., Ltd. today began demonstration testing on public roads in Japan of the GIGA FUEL CELL, a fuel cell (FC)-powered heavy-duty truck currently being co-developed by the two companies.
  • Through this demonstration testing, scheduled to run through September 2024, the two companies will continue making progress in collecting data, amassing knowledge and identifying technical issues in preparation for a 2027 market introduction.
  • The prototype model being used for this demonstration testing is the same type as the one exhibited at the Isuzu Group booth at the JAPAN MOBILITY SHOW 2023.
  • With the cooperation of Isuzu Logistics Co., Ltd. and Honda Logistics Inc., the logistics companies of Isuzu Group and Honda Group, respectively, demonstration testing of the GIGA FUEL CELL will be conducted on public roads in Japan to verify the potential of the utilization of hydrogen fuel and the practicality of FC trucks.

AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

Retrieved on: 
Tuesday, November 28, 2023

AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET

Key Points: 
  • AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET
    AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease.
  • This live webcast will provide further details on:
    The presentation will be followed by a Q&A session.

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

MedCerts and University of the Virgin Islands CELL Announce Partnership

Retrieved on: 
Monday, November 27, 2023

University of the Virgin Islands – Center for Excellence in Leadership and Learning (UVI CELL) has partnered with MedCerts , a leader in online healthcare training and information technology career training, to offer students a number of healthcare training programs and exam preparation opportunities.

Key Points: 
  • University of the Virgin Islands – Center for Excellence in Leadership and Learning (UVI CELL) has partnered with MedCerts , a leader in online healthcare training and information technology career training, to offer students a number of healthcare training programs and exam preparation opportunities.
  • “We want to present limitless possibilities that are flexible and easily accessible to students,” said Dr. Suzanne Darrow-Magras, UVI CELL Director.
  • “MedCerts programs will help students gain the skills they need to thrive in their desired careers.”
    The programs and exam preparation MedCerts will offer through the partnership with UVI CELL will prepare students for success in a variety of medical careers, including:
    With industry reports showing that healthcare continues to be the fastest growing industry, MedCerts and UVI CELL plan to effectively prepare students for these increasing opportunities.
  • The company has developed more than 50 immersive online national certification training programs, combined with onsite training experiences.

QUAQ solution powers ELFBAR and LOST MARY

Retrieved on: 
Tuesday, December 5, 2023

LONDON, Dec. 5, 2023 /PRNewswire/ -- Global vaping solution provider QUAQ showcases its trio of technologies across new ELFBAR and LOST MARY-branded products.

Key Points: 
  • LONDON, Dec. 5, 2023 /PRNewswire/ -- Global vaping solution provider QUAQ showcases its trio of technologies across new ELFBAR and LOST MARY-branded products.
  • LOST MARY's TAPPO is the latest in a series of vape products on which QUAQ is adopted, including ELFBAR 600V2, ELFA PRO and LOST MARY BM600S.
  • Turbocharged by QUAQ CELL and MESH, BM600S promises to continue the top-selling momentum of LOST MARY BM600.
  • As LOST MARY's first prefilled pod system tailored for the European market and esteemed as the brand's flagship offering, TAPPO also pioneers the integration of all three QUAQ technologies.

QUAQ unveils in Saudi Arabia and UAE with ELFBAR BC10000

Retrieved on: 
Tuesday, November 21, 2023

JEDDAH, Saudi Arabia, Nov. 21, 2023 /PRNewswire/ -- Global vaping solution provider QUAQ announced its latest atomizing technologies in Saudi Arabia and the UAE, joining hands with world leading vape brand ELFBAR and its unprecedented ultra-big-puff BC10000 device.

Key Points: 
  • JEDDAH, Saudi Arabia, Nov. 21, 2023 /PRNewswire/ -- Global vaping solution provider QUAQ announced its latest atomizing technologies in Saudi Arabia and the UAE, joining hands with world leading vape brand ELFBAR and its unprecedented ultra-big-puff BC10000 device.
  • This pillar technology, QUAQ MESH, makes up the trio-technology solution that sports vaping products under leading global brands, including ELFBAR.
  • QUAQ CELL is the industry's first atomizing power integration, and QUAQ CAPSULE sets the benchmark for the industry's cartridge solution.
  • BC10000 is now available through multiple channels in Saudi Arabia and the UAE.

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

Retrieved on: 
Tuesday, October 31, 2023

Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient’s own NK-cells to effect cancer surveillance, recognition, and killing.

Key Points: 
  • INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition.
  • The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™.
  • “Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,” said Joshua Schoonover, Esq., in-house General Counsel for the Company.
  • INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients.